1. Platelet and liver regeneration after liver surgery
   Kazuhiro Takahashi et al, 2020, Surgery Today CrossRef
2. From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag
   Harinder Gill et al, 2017, Therapeutic Advances in Hematology CrossRef
3. Eltrombopag Improves Erythroid Differentiation in a Human Induced Pluripotent Stem Cell Model of Diamond Blackfan Anemia
   Husam Qanash et al, 2021, Cells CrossRef
4. Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells
   Sandra Muntión et al, 2022, Therapeutic Advances in Hematology CrossRef
5. Novel Perspectives on Thrombopoietin Receptor Agonists Applications
   Christos Stafylidis et al, 2024, Hämostaseologie CrossRef
6. Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ
   Luigi J. Alvarado et al, 2019, Blood CrossRef
7. Effects of Iron Chelation in Osteosarcoma
   Maura Argenziano et al, 2021, Current Cancer Drug Targets CrossRef
8. Platelets in liver disease, cancer and regeneration
   Tomohiro Kurokawa et al, 2017, World Journal of Gastroenterology CrossRef
9. The preoperative alkaline phosphatase-to-platelet ratio index is an independent prognostic factor for hepatocellular carcinoma after hepatic resection
   Ya-Qun Yu et al, 2016, Medicine CrossRef
10. Emerging Roles of the Iron Chelators in Inflammation
    Alessandra Di Paola et al, 2022, International Journal of Molecular Sciences CrossRef
11. Role of Platelet, Blood Stem Cell, and Thrombopoietin in Liver Regeneration, Liver Cirrhosis, and Liver Diseases
    Tomohiro Kurokawa et al, 2018, Stem Cells and Cancer in Hepatology CrossRef
12. Identification of Eltrombopag as a Repurposing Drug Against Staphylococcus epidermidis and its Biofilms
    Juan Zhu et al, 2021, Current Microbiology CrossRef
13. Discovery of the anti-angiogenesis effect of eltrombopag in breast cancer through targeting of HuR protein
    Yuying Zhu et al, 2020, Acta Pharmaceutica Sinica B CrossRef
14. Stable Liver Function during Long-Term Administration of Eltrombopag, a Thrombopoietin Receptor Agonist, in Patients with Chronic Liver Disease
    Tomohiro Kurokawa et al, 2016, The Tohoku Journal of Experimental Medicine CrossRef
15. Mechanisms and therapeutic prospects of thrombopoietin receptor agonists
    James Bussel et al, 2019, Seminars in Hematology CrossRef
16. Early immunomodulation in immune thrombocytopenia—A report of the ICIS meeting in Lenzerheide, Switzerland 2022
    Tomás José González‐López et al, 2023, British Journal of Haematology CrossRef
17. Reductive metabolism of azo dyes and drugs: Toxicological implications
    P. David Josephy et al, 2023, Food and Chemical Toxicology CrossRef
18. Repurposing Eltrombopag as an Antimicrobial Agent Against Methicillin-Resistant Staphylococcus aureus
    Pengfei She et al, 2022, Frontiers in Microbiology CrossRef
19. Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication
    Torin Waters et al, 2020, BMC Cancer CrossRef
20. Osteosarcoma in Children: Not Only Chemotherapy
    Maura Argenziano et al, 2021, Pharmaceuticals CrossRef
21. Eltrombopag: a powerful chelator of cellular or extracellular iron(III) alone or combined with a second chelator
    Evangelia Vlachodimitropoulou et al, 2017, Blood CrossRef
22. Platelets in chronic liver disease, from bench to bedside
    Pierluigi Ramadori et al, 2019, JHEP Reports CrossRef